MAIA Biotechnology, Inc. Income Statement
MAIA|3 years of annual SEC 10-K data (FY2022-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$0
FY2024
Gross Profit
N/A
FY2024
Operating Income
-$17M
FY2024
Net Income
-$23M
FY2024
MAIA Biotechnology, Inc. reported $0 in revenue and $23M in net loss for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| SG&A Expense | $6.9M | $6.1M | $4.3M |
| R&D Expense | $10.0M | $8.9M | $3.5M |
| Operating Income | -$17.0M | -$16.2M | -$7.8M |
| Interest Expense | $57 | $7.0K | $827.5K |
| Income Tax | $2.0K | - | - |
| Net Income | -$23.3M | -$15.8M | -$12.6M |
| EPS (Basic) | -$1.49 | -$1.75 | -$2.37 |
| EPS (Diluted) | -$1.49 | -$1.75 | -$2.37 |
| Shares Outstanding | 17.0M | 11.0M | 7.6M |